Skip to main
PASG

PASSAGE BIO (PASG) Stock Forecast & Price Target

PASSAGE BIO (PASG) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 20%
Hold 40%
Sell 0%
Strong Sell 0%

Bulls say

Passage Bio is financially sound, with a strong focus on developing and advancing one-time gene therapies tailored to treat neurodegenerative diseases. The company's pipeline, with its lead candidate PBFT02, shows promise for addressing critical underlying pathologies and has the potential for significant revenue growth. With the projected 5x multiple to peak sales and a reasonable discount rate, Passage Bio's stock has the potential for positive returns for investors in the long term.

Bears say

Passage Bio is in a difficult position, with regulatory uncertainties and challenges in conducting clinical trials for their lead program PBFT02, leading to a downgrade from Outperform to Neutral for the stock. This is further exacerbated by the company's limited cash runway and competition in the indications they are pursuing. While the biomarker data from their upliFT-D study shows potential for clinical benefit, the lack of flexibility from the FDA and the significant resources and time needed for a randomized controlled study make success for Passage Bio's programs uncertain.

PASSAGE BIO (PASG) has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 20% recommend Buy, 40% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of PASSAGE BIO and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About PASSAGE BIO (PASG) Forecast

Analysts have given PASSAGE BIO (PASG) a Buy based on their latest research and market trends.

According to 5 analysts, PASSAGE BIO (PASG) has a Buy consensus rating as of May 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

PASSAGE BIO (PASG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.